<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01313065</url>
  </required_header>
  <id_info>
    <org_study_id>VX15/2503-01 v.9</org_study_id>
    <nct_id>NCT01313065</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety, Tolerability, PK &amp; PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of VX15/2503 in Adult Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaccinex Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vaccinex Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of IV administration of&#xD;
      VX15/2503 in patients with advanced solid tumors. The escalation part of the study will&#xD;
      determine the maximum tolerated dose (MTD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VX15/2503-01 is a dose-escalation, open label study to evaluate the safety and tolerability&#xD;
      of IV administered VX15/2503 in patients with advanced solid tumors. This will be&#xD;
      accomplished by using a dose escalation procedure starting at low doses of VX15/2503 and will&#xD;
      continue based on predefined parameters until the maximum tolerated dose is identified.&#xD;
&#xD;
      The study drug, VX15/2503, is a monoclonal antibody that binds to the semaphorin 4D (SEMA4D;&#xD;
      CD100) antigen. Semaphorins have been shown to play an important role in certain&#xD;
      physiological processes such as vascular growth, tumor progression and immune cell&#xD;
      regulation. Experimental evidence suggests that SEMA4D has two mechanisms of action that&#xD;
      result in angiogenesis and tumor proliferation and invasion. Antibody neutralization of&#xD;
      SEMA4D thus may represent a new therapeutic strategy for cancer treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/tolerability as measured by number of patients with adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Subject incidence of treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose as measured by frequency of dose limiting toxicities</measure>
    <time_frame>Four (4) weeks after first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) of VX15/2503</measure>
    <time_frame>Four (4) hours after start of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of VX15/2503</measure>
    <time_frame>Up to seven (7) days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of VX15/2503</measure>
    <time_frame>Up to 14 days after first dose</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>SEMA4D T cell percent saturation of VX15/2503</measure>
    <time_frame>Up to 18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients who develop anti-drug antibody</measure>
    <time_frame>Up to 18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall response rate (ORR) using RECIST 1.1</measure>
    <time_frame>Up to 18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Progression-free survival (PFS) using RECIST 1.1</measure>
    <time_frame>Up to 18 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>VX15/2503</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VX15/2503 monoclonal antibody at a concentration of 0.3 mg/kg - 20 mg/kg to be administered intravenously on a weekly dosing cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX15/2503</intervention_name>
    <description>Dose escalation will begin at low doses and will gradually increase in each future cohort. The current trial design provides for 7 study cohorts with a 20 mg/kg expansion phase.</description>
    <arm_group_label>VX15/2503</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 yrs or older with confirmed histological or cytological advanced solid&#xD;
             tumors, relapsed or refractory to standard treatment for which no curative therapy is&#xD;
             available; patients must demonstrate progressive disease prior to entry&#xD;
&#xD;
          -  Has measurable disease as defined by RECIST1.1&#xD;
&#xD;
          -  Life expectancy of at least 3 months (per investigator assessment)&#xD;
&#xD;
          -  ECOG performance status of 0-2&#xD;
&#xD;
          -  Adequate bone marrow, renal and liver function&#xD;
&#xD;
          -  Recovered from any significant prior toxicity of previous anti-neoplastic therapy&#xD;
&#xD;
          -  For patients of reproductive potential, is willing to use a medically acceptable form&#xD;
             of contraception throughout the study period and for at least 4 weeks after the last&#xD;
             dose of VX15/2503&#xD;
&#xD;
          -  Expansion cohort - patients in this cohort must have one of the following&#xD;
             characteristics:&#xD;
&#xD;
          -  A diagnosis of a pancreatic neuroendocrine tumor OR&#xD;
&#xD;
          -  A diagnosis of a soft tissue sarcoma OR&#xD;
&#xD;
          -  A diagnosis of a bone metastasis OR&#xD;
&#xD;
          -  A diagnosis of advanced solid tumor AND a T cell count of at least 1500 cells/uL OR a&#xD;
             B cell count of at least 250 cells/uL at screening&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with anti-neoplastic agents (chemotherapy, immunotherapy, radiotherapy or&#xD;
             endocrine therapy) within 3 weeks prior to start of study treatment&#xD;
&#xD;
          -  Treatment with an investigational agent within 4 weeks prior to start of study&#xD;
             treatment&#xD;
&#xD;
          -  Is on concurrent anti-neoplastic therapy with the exception of continuing luteinizing&#xD;
             hormone-releasing hormone agonist/antagonist therapy for patients with&#xD;
             castrate-resistant prostate cancer&#xD;
&#xD;
          -  Treatment with oral or parenteral corticosteroids in excess of 10mg/day of&#xD;
             prednisolone or equivalent for more than 5 days within 4 weeks prior to start of study&#xD;
             treatment or a requirement for systemic immunosuppressive therapy for any reason&#xD;
&#xD;
          -  Untreated brain Mets or CNS tumor involvement&#xD;
&#xD;
          -  Any other intercurrent illness or condition which could impact patient compliance or&#xD;
             ability to complete the study&#xD;
&#xD;
          -  Sensitivity to VX15/2503 or the ingredients or excipients of VX15/2503&#xD;
&#xD;
          -  Pregnant or breast-feeding women (women of child-bearing potential must have negative&#xD;
             serum pregnancy test within 3 days prior to receiving the first dose of VX15/2503)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amita Patnaik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Texas Accelerated Research Therapeutics, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramesh K Ramanathan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TGen Clinical Research Service at Scottsdale Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia G. Piper Cancer Center at Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>March 4, 2011</study_first_submitted>
  <study_first_submitted_qc>March 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2011</study_first_posted>
  <last_update_submitted>August 11, 2014</last_update_submitted>
  <last_update_submitted_qc>August 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VX15/2503</keyword>
  <keyword>Semaphorin 4D</keyword>
  <keyword>SEMA4D</keyword>
  <keyword>CD100</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>advanced solid tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

